CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia
Authors:
Open Access
- 25 January 2021
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1-13
Abstract
Background: Leukemia stem cells (LSCs) are responsible for the initiation, progression, and relapse of acute myeloid leukemia (AML). Therefore, a therapeutic strategy targeting LSCs is a potential approach to eradicate AML. In this study, we aimed to identify LSC-specific surface markers and uncover the underlying mechanism of AML LSCs. Methods: Microarray gene expression data were used to investigate candidate AML-LSC-specific markers. CD9 expression in AML cell lines, patients with AML, and normal donors was evaluated by flow cytometry (FC). The biological characteristics of CD9-positive (CD9+) cells were analyzed by in vitro proliferation, chemotherapeutic drug resistance, migration, and in vivo xenotransplantation assays. The molecular mechanism involved in CD9+ cell function was investigated by gene expression profiling. The effects of alpha-2-macroglobulin (A2M) on CD9+ cells were analyzed with regard to proliferation, drug resistance, and migration. Results: CD9, a cell surface protein, was specifically expressed on AML LSCs but barely detected on normal hematopoietic stem cells (HSCs). CD9+ cells exhibit more resistance to chemotherapy drugs and higher migration potential than do CD9-negative (CD9−) cells. More importantly, CD9+ cells possess the ability to reconstitute human AML in immunocompromised mice and promote leukemia growth, suggesting that CD9+ cells define the LSC population. Furthermore, we identified that A2M plays a crucial role in maintaining CD9+ LSC stemness. Knockdown of A2M impairs drug resistance and migration of CD9+ cells. Conclusion: Our findings suggest that CD9 is a new biomarker of AML LSCs and is a promising therapeutic target.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81572464, 81602590)
- Fundamental Research Funds for the Central Universities (1061120206, 2019CDYGZD008)
- National key research and development program (2016YFC1303405)
- National Science Foundation of Chongqing (cstc2016shms-ztzx10006)
This publication has 48 references indexed in Scilit:
- Activated α2-Macroglobulin Regulates Transcriptional Activation of c-MYC Target Genes through Cell Surface GRP78 ProteinJournal of Biological Chemistry, 2016
- T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemiaCurrent Opinion in Hematology, 2015
- Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification2014
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionBlood, 2013
- Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study GroupJournal of Clinical Oncology, 2011
- Strategies for Homeostatic Stem Cell Self-Renewal in Adult TissuesCell, 2011
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2010
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cellsBiochemical and Biophysical Research Communications, 2009
- Specific tetraspanin functionsJournal of Cell Biology, 2001